“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Progressing towards the development of
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
The launched product is from Lupin’s Pithampur manufacturing facility
Mumbai, Baltimore, July 05, 2017: Pharma Major Lupin Limited (Lupin) announced the launch of its Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5% (base) having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5% (base), is an AT1 rated generic equivalent of Novartis Pharms Corp.’s Vigamox® Ophthalmic solution. It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the organisms.
Vigamox® Ophthalmic solution had US sales of USD 267.9 million (IMS MAT March 2017).
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 4th and the 6th largest generics pharmaceutical company by market capitalization and revenues globally (March 31st, 2017, Bloomberg). The Company is the 4th largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT March 2017); the 2nd largest Indian pharmaceutical company by global revenues; the 6th largest generic pharmaceutical player in Japan and the 6th largest company in Indian Pharmaceutical Market (Quintiles IMS MAT March 2017).
For the financial year ended 31st March, 2017, Lupin’s Consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinlimited
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries please contact –
VP – Corporate Communications
Head – IR and M&A
*Safe Harbor Statement
Vigamox® is registered trademark of Novartis AG.